ArticleIndian journal of ophthalmology2026
Cavitary retinoblastoma: Clinical features and treatment outcomes.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe clinical characteristics and treatment outcomes of children diagnosed with cavitary retinoblastoma (RB).
methodsRetrospective analysis of children treated for cavitary RB.
resultsOf the 40 patients (43 eyes) with cavitary RB, 14 (35%) were female and 26 (65%) were male. At diagnosis, the average age was 25 months (median, 24 months; range 3-84 months). In 3 cases (8%), bilateral cavitary RB was seen. The most prevalent presenting symptoms were leukocoria (n = 21, 53%) and strabismus (n = 6, 15%) with a mean duration of symptoms of 23 weeks (median, 16 weeks; range 0-104 weeks). As per the ICRB classification, 15 eyes (35%) were in group D, 12 eyes (28%) in group C, 10 eyes (23%) in group B, and 6 eyes (14%) in group E. Primary cavities, within the tumor, were seen in 14 eyes (33%), whereas secondary cavities were seen in 29 eyes (67%). Most of the eyes (n = 42, 98%) were treated with intravenous chemotherapy (IVC), and one eye (2%) received intra-arterial chemotherapy. In ten eyes (23%), the tumor recurred following IVC, and two cases exhibited a partial response to IVC. At the last follow-up (mean, 31 months), all eyes (100%) had local tumor control with no evidence of systemic metastasis or death. Regression of the cavities within the tumor was noted in 27 eyes (63%), while it remained stable in 16 eyes (37%).
conclusionCavitary RB (both primary and secondary) had a good initial response to standard chemotherapy with an overall excellent prognosis for globe salvage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.